Navigation Links
Proove Biosciences Exhibits Industry Leading Data and Research at PAINWeek 2014
Date:9/3/2014

IRVINE, CA and ANNAPOLIS JUNCTION, MD (PRWEB) September 03, 2014

Proove Biosciences, the commercial and research leader in personalized medicine, will be exhibiting data and research conducted through their latest proprietary testing services at this year’s PAINWeek, the nation’s largest pain conference for clinicians in pain management. This year’s conference is taking place this week at The Cosmopolitan of Las Vegas.

PAINWeek offers a multidisciplinary faculty and diverse curriculum in several pain concentrations including behavioral pain management, diabetes and pain, interventional pain management, chemical dependency and pharmacotherapy. Over 1,800 physicians, physician assistants, nurse practitioners, pharmacists, and social workers are expected to attend this year.

“PAINWeek is the industry’s leading conference dedicated to promoting the latest and most ground breaking science and treatment options for pain from all sources,” stated Proove Biosciences CEO, Brian Meshkin. “Proove Biosciences has been recognized as a leader in personalized pain medicine and genetic testing, and uses evidence-based research to help physicians and patients better understand and treat their pain.”

Major components of this year’s forum will be emerging and alternative technologies in interventional pain management, and how genetics and gender play a vital role patient pain and pain management.

“We are looking forward to exhibiting three posters of data, and explaining how our research is helping patients better manage and understand their pain, while lowering the associated healthcare costs and increasing prescription efficiency. Proove researcher and team member, Dr. Derrick Holman will be present at the conference to illustrate how Proove’s science is helping physicians realize the promise of personalized medicine.”

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2014/09/prweb12139809.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
5. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
6. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
7. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
8. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
9. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
10. Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting
11. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Biotechnology: Emerging Technologies and Global Markets" report to their ... ... next generation DNA sequencing, biochips, RNA interference, synthetic biology tools ... seeds; and biologicals. These technologies and products are ...
(Date:3/28/2017)... ... March 28, 2017 , ... Mass spectrometry is becoming more widely for ... is driven by its potential to perform challenging analyses in complex matrices and sample ... must be addressed for it to be routinely used for medical testing. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of the Modular Building Institute (MBI), an international modular trade organization, were awarded ... modular category for the Pagliuca Life Lab at Harvard University. The awards were ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  The National ... has joined the health policy research organization as its ... Medical and Regulatory Affairs ( North America ... Board of Directors. "We,re pleased to have ... NPC President Dan Leonard . "We welcome their ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):